TERMIS-EU Meeting 2010

Victor Dzau, MD, was appointed President and CEO of Duke University's Health System and Chancellor for Health Affairs at Duke University effective from July 1, 2004. He also serves as a member of the Board of Directors for Genzyme Corporation. He has also been elected chairman of the Institute of Medicine of the National Academy of Sciences (USA), the European Academy of Sciences and Arts and the National Institutes of Health. He is also the James B. Duke Professor of Medicine and Director of Molecular and Genomic Vascular Biology at Duke. Before coming to Duke, Dzau was the Hersey Professor of the Theory and Practice of Physic (Medicine) at Harvard Medical School, chairman of the Department of Medicine at Brigham and Women's Hospital, and physician in chief and director of research at Brigham and Women's Hospital, Boston. Prior to this post, he served as Arthur Bloomfield Professor and chairman of the Department of Medicine at Stanford University.
To continue reading click here

Helen M. Blau, Ph.D., is the Donald E. and Delia B. Baxter Professor, the Director of the Baxter Laboratory for Stem Cell Biology in the Department of Microbiology and Immunology and a member of the new Institute of Stem Cell Biology and Regenerative Medicine at Stanford University School of Medicine. Professor Blau's research area is in cell and developmental biology.  She has had a longstanding interest in stem cell biology and cell specialization, and is especially well known for her research demonstrating plasticity of the differentiated state. Her muscle heterokaryon experiments proved that silent muscle genes can be activated in diverse adult human specialized cells and that the differentiated state is dynamic, ongoing, and dictated by the balance of regulators at any given time
To continue reading click here

Randall Moon is Director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington, School of Medicine in Seattle. He is also Professor of Pharmacology and the William and Marilyn Connor Chair at the University of Washington, School of Medicine. Randall Moon is also a scientific founder of Fate Therapeutics, a private biotech company interrogating adult stem cell biology and which applies induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds which guide cell fate for therapeutic purposes.
To continue reading click here

Hans-Dieter Volk is Director of the Institute of Medical Immunology and the Berlin-Brandenburg Center for Regenerative Therapies. Several biotech enterprises have been established from technology platforms developed at his Institute (Probiogen AG, Jerini AG, Cellserve GmbH). Several biomarker assays developed at the institute were commercialized.

Prof Volk's research bridges the gap between basic research and clinical research. His work focuses on the implementation of new approaches in the diagnosis and treatment of immunological diseases.
To continue reading click here

David Williams was trained as a materials scientist at the University of Birmingham, UK (B.Sc. 1965, Ph.D. 1969, D.Sc. 1982). In 1968 he took up a faculty position in the School of Medicine at the University of Liverpool, UK, where he remained for 40 years, writing, researching and teaching on the science of biomaterials. He created the Department of Clinical Engineering in the University and was its Head for 20 years. He was granted a Personal Chair in the University in 1984, then the youngest person in the history of the University to receive such an honour. Towards the end of his career in Liverpool, he became the Pro-Vice-Chancellor (equivalent to Academic Vice-President) of the University, and then won major funding from the British Government to form, in collaboration with the University of Manchester, the UK Centre for Tissue Engineering, of which he became Director.
To continue reading click here

Mark Ferguson is the Co-founder (with Dr Sharon O'Kane) and CEO of Renovo a Biotechnology Company spun out of the University of Manchester, which is developing novel pharmaceutical therapies to prevent scarring or accelerate healing following wounding (www.renovo.com). Following two rounds of private venture capital funding (totalling £32M) Renovo successfully completed an IPO on the Main list of the London Stock Exchange in April 2006, raising £67.5M. Renovo partnered its lead drug, Juvista for scar reduction, with Shire in a $825M plus royalties deal retaining all EU rights, where it intends to commercialise itself. Renovo has three drugs in the clinic: Juvista in PhIII, with 8 clinically and statistically significant PII efficacy trials, Juvidex, Adaprev and Prevascar in PII, and over a dozen preclinical candidates. Since the age of 28, Mark Ferguson has been Professor in the School of Biological Sciences at the University of Manchester, where he has held a number of administrative posts including Head of Department and Dean.
To continue reading click here

Peter Johnson is Executive Vice President and Chief Business Officer of Entegrion, a life sciences company based in North Carolina's Research Triangle Park that commercialises technologies developed at the University of North Carolina. Prior to joining Entegrion, Peter Johnson was the Founder, President and CEO of Scintellix, a highly successful biomedical technology and decision analysis consultancy in Raleigh, North Carolina.

In addition to practicing Plastic Surgery for ten years at the University of Pittsburgh, Peter Johnson founded and was the first President of the Pittsburgh Tissue Engineering Initiative. He also co-founded and served as Chairman and CEO of Tissue Informatics.
To continue reading click here

James Kirkpatrick has a triple doctorate in science and medicine from the Queen's University of Belfast in Ireland and since 1993 is Professor of Pathology and Chairman of the Institute of Pathology at the Johannes Gutenberg University of Mainz, Germany. Previous appointments were in pathology at the University of Ulm, Manchester University and the RWTH Aachen. His principal research interests are in the fields of endothelial pathobiology, biomaterials in tissue engineering and regenerative medicine, with special focus on the development of human cell culture techniques, especially in co-culture systems in three-dimensions. During the past years his work has involved endothelial progenitor cells for vascularization in tissue engineering strategies, as well as barrier models to study nanoparticle interactions with cellular systems.
To continue reading click here

Alan J. Russell, PhD , Director, McGowan Institute for Regenerative Medicine
Dr. Alan Russell (Ph.D. in Biological Chemistry, 1987, Imperial College of Science and Technology, University of London) is a Distinguished University Professor of Surgery and the Founding Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. Further, he holds positions as the Executive Director of the Pittsburgh Tissue Engineering Initiative, Inc., as the Director of the National Tissue Engineering Center, as well as Professor in the Rehabilitation Science and Technology Department, Professor in the Bioengineering Department, and Professor in the Chemical Engineering Department. In addition to his appointments at the University, Dr. Russell consults for UPMC's (University of Pittsburgh Medical Center) International and Commercial Services Division to drive technology and science-based synergies and partnerships.
To continue reading click here